CollPlant (CLGN) VP reports 25,000 RSUs with 4-year vesting

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd executive Bagley Bowman, VP Commercial North America, filed an initial ownership report showing 25,000 restricted share units. These RSUs vest over four years: 25% on January 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bagley Bowman

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Commercial North America

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Share Units	25,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted share units shall vest over a period of 4 years as follows: 25% shall vest on January 1, 2027, and the remaining 75% shall vest in twelve equal quarterly installments thereafter.

	/s/ Bowman Bagley	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position is reported for CLGN executive Bagley Bowman?

Bagley Bowman, VP Commercial North America at CollPlant Biotechnologies, reported holding 25,000 restricted share units. This Form 3 filing is an initial ownership statement, showing Bowman's equity-based interest in the company through these RSUs, subject to a multi-year vesting schedule.

How many restricted share units does the CLGN VP hold according to the Form 3?

The Form 3 shows that CollPlant’s VP Commercial North America holds 25,000 restricted share units. These units represent a right to receive company shares in the future, once the vesting conditions described in the filing are satisfied over the four-year period.

What is the vesting schedule for Bagley Bowman’s 25,000 CLGN restricted share units?

The restricted share units vest over four years. According to the filing, 25% will vest on January 1, 2027, and the remaining 75% will vest in twelve equal quarterly installments following that initial vesting date.

Does the CLGN Form 3 show any insider share purchases or sales?

The Form 3 is an initial ownership report and does not show any buy or sell transactions. It discloses that the executive holds 25,000 restricted share units, which will vest over time, rather than documenting open-market trading activity.

What type of security is reported in CollPlant Biotechnologies VP’s Form 3?

The security reported is restricted share units. These RSUs give the CollPlant Biotechnologies VP Commercial North America a future right to receive company shares, subject to the four-year vesting schedule detailed in the filing’s footnote.

Over what timeframe will the CLGN executive’s RSUs fully vest?

The RSUs are scheduled to vest over a four-year period. A quarter of the award vests on January 1, 2027, and the remaining three-quarters vest through twelve equal quarterly installments after that date until fully vested.